Absci is trading 6.8% down at $9.36, with broader risk-off conditions possibly weighing on shares. - Shares closed at $10.04 on October 21. - No clear company-specific announcement explaining the decline surfaced in available coverage. - Markets are lower amid geopolitical tensions and rising oil prices; Bloomberg reports higher Treasury yields are denting appetite for biotechnology stocks.